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SYNERGISTIC EFFECT OF COMBINING PARP INHIBITOR (AZD2281) AND 
ATR INHIBITOR (AZD6738) IN EWING SARCOMA CELL LINES 
STEPHANIE CORINNE MEYER 
ABSTRACT 
 Ewing Sarcoma (ES) is an aggressive pediatric solid tumor. Even though overall-
survival for localized patients is approximately 70%, the overall-survival for high risk ES 
patients has not improved in the last 20 years. Therefore, there is a need for exploration 
of new therapeutic agents in ES. Recent evidence has demonstrated that ES cells behave 
like BRCA-deficient tumor types which renders them sensitive to PARP inhibitors in 
vitro and in vivo. However, a phase II study of the efficacy of single-agent PARP 
inhibition in patients with relapsed ES did not significantly improve outcome. As single-
agent therapy is rarely expected to result in significant clinical responses, in this study, 
we plan to validate potential targeted combination therapies with PARP inhibitors in ES. 
Since ES appears to demonstrated BRCA-deficient biology with impaired 
homologous recombination, cells are expected to be sensitive to both PARP inhibitors 
and ATR inhibitors, drugs which have a role in regulating DNA damage and impairing 
homologous recombination. In breast cancer and ovarian cell lines with genetic BRCA-
deficiency, PARP and ATR inhibitors have synergistic activity. We hypothesize that 
these inhibitors will also have synergistic anti-Ewing activity. Furthermore, we recognize 
that ES cells demonstrate remarkably quiet genomes suggesting that there is minimal 
ongoing DNA-damage when cells are growing unperturbed. Therefore, we also plan to 
test the effect of adding low-dose genotoxic chemotherapy to induce additional 
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sensitivity to the combination of PARP and ATR inhibitors in ES.   The specific aims of 
this study were to explore the possible anti-tumor effect of PARP inhibitors combined 
with ATR inhibitors in ES cell lines, and to explore whether low dose genotoxic 
chemotherapy with SN38 can potentiate the anti-tumor effect of combined PARP and 
ATR inhibition in ES cell lines.  
We studied the anti-Ewing Sarcoma effect of the combination of a PARP 
inhibitor, AZD2281, and an ATR inhibitor, AZD6738, across a range of doses with and 
without low doses of a DNA damaging agent, SN38 (irinotecan metabolite), in two ES 
cell lines. We analyzed synergy by determining the Combination Index (CI) and 
Fractional Inhibition (FA) of each combination.  
We found that the ATR inhibitor, AZD6738, was synergistic across large range of 
concentrations when combined with the PARP inhibitor, AZD2281, in ES cell lines. We 
also found that treatment of cells with low doses of SN38 increases ES cell sensitivity to 
treatment with the PARP inhibitor and ATR inhibitor combination.  
This study provides preclinical support for additional studies exploring these 
combinations in ES. Given the low number of pediatric patients with ES compared to 
adult cancer patients, there will be limited attempts in combining these agents in clinical 
trials. Therefore, the development of an in vivo trial testing the safety and efficacy of this 
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Ewing’s Sarcoma (ES) is a highly malignant tumor found in adolescents and 
young adults with the majority of cases arising from bone and a significant number from 
soft tissue. It is the second most common bone tumor in children after osteosarcoma 
(Arndt, Rose, Folpe, & Laack, 2012). ES accounts for approximately 2% of all pediatric 
childhood cancers in the United States (Figure 1). Roughly 225 adolescents and children 
per year are diagnosed with ES in North America with these tumors being more common 
among non-Hispanic and Hispanic whites. ES predominantly occurs in teens but can also 
affect young children and adults in their 20s and 30s (American Cancer Society, 2018).  
 
Figure 1: Incidence of pediatric cancer in the United States. Percent incidence of 
Ewing’s Sarcoma (black) in 12,500 cases per year of pediatric cancers in the United 




ES is characterized by the fusion between the EWSR1 gene on chromosome 22 
and its ETS family partner (e.g. FLI1, ERG, ETV4, ETV1, FEV1). 80-90% of cases have 
translocations between EWSR1 and FLI1, while 5-10% are EWS-ERG. It is not currently 
fully understood what causes these gene changes (Sorensen et al., 1994). The EWSR1 
gene provides instruction for creating multifunctional EWS protein involved in gene 
expression, cell signaling, and RNA processing and transport. The ETS family is a group 
of transcriptional activators which bind DNA and regulate transcription.  EWS-ETS 
translocations result in the production of a chimeric protein involved in tumorigenesis. 
The EWS-FLI1 protein has the DNA-binding function of the FLI protein and the 
transcriptional regulation function of the EWS protein (Genetic Home Reference, 2018).   
ES often manifests itself as swelling and/or pain in the bone or joint (Grier et al., 
2003). The most common primary sites of ES are the pelvis, chest wall, and in the middle 
of long bones of the leg. Common sites of metastasis include lungs, other bony sites and 
bone marrow (American Cancer Society, 2018).  
Patients with newly-diagnosed localized ES have a 5-year Overall Survival (OS) 
of 65%-75%. However, OS for high-risk ES patients has remained low for the past 20 
years. Patients presenting with metastatic disease have a 5-year OS of <30% (Gaspar et 
al., 2015). Patients with metastasis isolated to the lungs do marginally better with a 3-
year Event-Free Survival (EFS) of 29% - 52% (Oberlin et al., 2006). Prognosis for 
patients with refractory or recurrent ES remains poor. Patients with local recurrence have 
a long-term survival of 22-24%, while those with distant relapse do even worse 
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(Rodríguez-Galindo et al., 2008). A study of primary disseminated multifocal ES found 
additional factors accounting for prognosis including: primary tumor volume greater than 
200mL,  age greater than or equal to 14 years old, and extent of metastatic spread 
(Ladenstein et al., 2010).  
 
Current Therapies Utilized in ES 
 
Patients with ES may be treated with chemotherapy and local control via radiation 
and/or surgery (Grier et al., 2003). Common upfront treatment of localized disease 
consists of cycles of vincristine, doxorubicin, cyclophosphamide (VDC) alternating with 
cycles of ifosfamide and etoposide (IE). After approximately 6 cycles of therapy, patients 
undergo local control therapy for all sites of disease whether local control surgery, 
radiation therapy, or both. Patients then receive additional cycles of VDC/IE. The most 
recently completed Children’s Oncology Group (COG) trial, AEWS0031, found that 
giving the intensified regimen of compressed VDC/IE every 2 weeks significantly 
improved the 5-year Event-Free Survival (EFS) to 73% compared to treatment with the 
same number of cycles of chemotherapy given every 3 weeks (5-year EFS = 65%) 
(Womer et al., 2012).  
While cure after relapse is rare, patients frequently do have temporary responses 
to therapy for recurrent disease (Gaspar et al., 2015). Treatments for patients with 
relapsed disease include topotecan plus cyclophosphamide, irinotecan plus 
temozolomide, or gemcitabine plus docetaxel. A retrospective study at Memorial Sloan-
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Kettering reported that of the 19 relapsed ES patients with evaluable disease treated with 
irinotecan and temozolamide, seven had progressive disease (Casey et al., 2009). Given 
the number of non-responders to these treatments, there is a need to find alternative 
agents including targeted agents to combat the disease.  
 
PARP Inhibitors  
 
Poly-ADP Ribose Polymerase-1 (PARP-1) is a key enzyme involved in detecting 
and initiating cellular response to single-strand DNA (ssDNA) breaks. PARP-1 
accelerates base excision repair by binding to DNA and causing rapid enzymatic 
activation of PARP-1 leading to poly(ADP-ribosyl)ation of numerous nuclear proteins, 
including itself. This modification causes PARP-1 to lose its affinity for DNA and be 
released from its DNA binding site. Therefore, modified DNA allows access of repair 
proteins such as DNA ligase III and DNA polymerase beta (Lindahl, Satoh, Poirier, & 
Klungland, 1995). PARP inhibitors inactive PARP-1 protein so it cannot be modified and 
may remain bound to damaged DNA for prolonged period of time leading to persistent 
ssDNA breaks, a phenomenon known as PARP trapping (Satoh & Lindahl, 1992).  
In the absence of PARP-1, ssDNA breaks cause replication forks to collapse and 
trigger homologous recombination for repair. PARP inhibitors alone are highly toxic for 
cells with mutations in BRCA1/2. BRCA 1/2 mutations cause defects in homologous 
recombination, thus leading cells to rely on PARP-mediated DNA damage repair 
mechanisms (Bryant et al., 2005).   
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A recent article demonstrates that ES is a BRCA-deficient-like tumor with 
impaired homologous recombination (Gorthi et al., 2018). The EWS-FLI protein causes a 
deficiency in wild-type EWSR1 functioning. In the absence of EWSR1, cells are unable 
to respond to DNA damage via BRCA1 mediated mechanisms of DNA repair, therefore 
increasing cells’ reliance on PARP activity in response to DNA damage (Gorthi et al., 
2018). This introduces the mechanistic basis for ES sensitivity to PARP-1 inhibitors.   
ES cells exhibit sensitivity to single agent PARP inhibitors, Olaparib and AG-
014699, at concentrations that are similar to BRCA-deficient cancer cells. (Garnett et al., 
2012). The overexpression of any of 3 ETS fusion genes (EWS-FLI, EWS-ERG, 
TMPRSS2-ERG) in cell lines causes increased sensitivity to Olaparib (Brenner et al., 
2012).  
A Phase II study of PARP inhibitor (Olaparib) in patients with refractory ES 
found that although Olaparib alone did not cause significant toxicities, it also did not 
induce significant responses or disease control (Choy et al., 2014). This however, is not 
surprising given that single-agent therapy is rarely expected to produce significant 
treatment response. Given this and preclinical evidence strongly supporting PARP 
inhibitors efficacy in ES, it is justified to continue exploring PARP inhibitors as a 
treatment in ES in combination with other agents.  
To identify candidate agents for combination with PARP inhibitors in clinical 
trials, one study screened a collection of ES chemotherapy agents and found the most 
significant synergistic anti-Ewing combination was PARP inhibition plus temozolamide 
and SN38, an irinotecan metabolite (Engert, Schneider, Weiβ, Probst, & Fulda, 2015).  
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PARP inhibitor mediated cytotoxicity can be potentiated by SN38/irinotecan and 
temozolamide in vitro in ES cell lines and in vivo in orthotropic ES xenografts. A 
Preclinical Phase III mouse study found a significant improvement in overall survival and 
outcome when a PARP inhibitor (Olaparib or BMN-673), was combined with irinotecan 
and temozolamide in an orthotopic ES mouse model (Stewart et al., 2014). The current 
challenge of implementing PARP inhibitors into the clinic has been the increased toxicity 
of combining PARP inhibitors with chemotherapy. Preliminary data from an ongoing 
Phase I trial studying PARP inhibitor (talazoparib) and irinotecan in children and young 
adults with recurrent/refractory solid tumors recommended a decreased dose of 
talazoparib and irinotecan due to dose-limiting toxicities including neutropenia, 
thrombocytopenia, and colitis. The decreased doses led to only 2/22 evaluable patients 
with response and nine other patients with disease stabilization  (Federico et al., 2017). 
Since the low number of responders could be, in part, explained by a need to decrease 
doses of PARP inhibitors and chemotherapy and since PARP inhibitors have shown 
efficacy in ES in preclinical models, studies of alternative, less toxic combinations with 
PARP inhibitors in ES are justified.   
 
Other strategies for implementing PARP-inhibition for BRCA-deficient cancer  
 




Ataxia telangiectasia and Rad3-related (ATR) protein is activated by replication 
stress and a variety of DNA damage including ssDNA breaks. ATR signaling protects the 
genome against DNA damage and replication stress by phosphorylating Chk1 and 
activating downstream pathways that regulate cell cycle arrest via the G2-M checkpoint, 
inhibition of replication, protection of stressed replication forks, and DNA repair (Karnitz 
& Zou, 2015).  ATR regulates several DNA repair pathways including homologous 
recombination. Cells with a deficiency in ATR are found to have a decreased frequency 
of homologous recombination and increased levels of chromosomal damage (Brown et 
al., 2014).  
Interestingly, in a PARP inhibitor synthetic lethal screen with a siRNA library of 
protein kinase and kinase associated genes in TP53 wild-type breast cancer cell lines, 
ATR was identified as the third highest scoring gene (Turner et al., 2008). Another study 
found that an ATR inhibitor, VE-821, sensitized ovarian cancer cells to the PARP 
inhibitor, Veliparib (Huntoon et al., 2013). PARP inhibitors and ATR inhibitors have also 
been found to be synergistic in the osteosarcoma cell line, U2OS  (Mohni et al., 2015).  
ATR inhibitors were found to disrupt BRCA1-independent RAD51 loading to double 
stranded breaks (DSB) and stalled replication forks in PARP inhibitor-resistant BRCA1-
deficient cells (Yazinski et al., 2017). Combining PARP inhibitors and ATR inhibitors in 
vivo in a BRCA2 mutant PDX model were shown to be synergistic by causing a 
statistically significant decrease in tumor volume in the combined ATR inhibitor and 
PARP inhibitor treatment group compared to each agent alone. 57% of mice treated with 
the combination had a complete response (Kim et al., 2017). Given this encouraging 
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preclinical data, there is a Phase II study combining ATR inhibition (AZD6738) and 
PARP inhibition (Olaparib) in recurrent ovarian cancer (clinicaltrials.gov, 
NCT03462342). Based on the sensitivity of ES cells to PARP inhibition and recent data 
confirming that ES cells have BRCA-deficient-like biology, we hypothesized that ATR 
inhibition would synergize with PARP inhibition in ES in vitro models.  
 
PARP Inhibitors combined with ATR inhibitors and SN38 (active metabolite of 
Irinotecan)  
  
Genomic sequencing data demonstrates a low rate of somatic mutations in ES 
suggesting that there is limited ongoing DNA damage in ES compared to other cancer 
types (Crompton et al., 2014). Therefore, we also hypothesized that the addition of low-
dose chemotherapy to induce genotoxic stress to ES cells could promote sensitivity to 
inhibitors of DNA-damage repair such as ATR and PARP inhibitors. Irinotecan (a DNA 
damaging agent) is currently being used in the relapse setting for patients with ES. Given 
this, we tested the effect of low-dose of SN38 (an active irinotecan metabolite) in order to 
sensitize ES cells to treatment with the combination of PARP and ATR inhibitors.  
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Specific Aims and Objectives 
Overall survival for high-risk ES patients has remained poor for the past 20 years. 
Therefore, there is an urgent need to identify new therapeutic agents for treatment of this 
disease. Recent evidence has shown how ES biology mimics BRCA-deficient tumor 
types and is sensitive to PARP inhibitors in vitro and in vivo. Since single-agent therapy 
is rarely curative in aggressive solid tumors and a Phase II study of single-agent PARP 
inhibition failed to improve outcome for patients with relapsed ES, we proposed to test 
the efficacy of combination therapy on ES cell lines. Based on recent studies that 
demonstrate synergistic activity between ATR and PARP inhibitors in BRCA-deficient 
cancers, we tested this combination in ES cells as outlined in the following specific aims:  
1. To explore the possible synergistic anti-tumor effect of PARP inhibitors 
combined with ATR inhibitors in ES cell lines.  
2. To explore whether low-dose SN38 can potentiate the anti-ES effect of combining 







Drug compounds used in this experiment included the PARP inhibitor, AZD2281, 
from Selleck, the ATR inhibitor, AZD6738, from Selleck, and the SN38 (active 
metabolite of irinotecan) from Fischer Scientific.  Compounds were diluted in DMSO to 




A673, SKPNDW, EW8 cells were grown in Dulbeccos’ Modified Eagle’s 
Medium (DMEM: Mediatech) with 10% FBS and 1%PSQ. 1mmol/L sodium pyruvate 
(Invitrogen) was added to A673 medium. TC32 and TC71 were grown in RPMI 
(Mediatech) with 10% FBS and 1% PSQ. All cell lines have unique genotypes that have 
been confirmed previously by RNA sequencing (Crompton et al., 2014).  
 
Dose response curves of ES cells to PARPi (AZD2281), ATRi (AZD6738), and SN38 
 
Dose response curves for PARPi, ATRi and SN38 were tested in five Ewing 
sarcoma cell lines (A673, TC32, TC71, SKPNDW, EW8). 96-well compound plates for 
each drug were created by 1:2 serial dilution in RPMI medium with 15% FBS. The drug 
plates were made at a 10-point, two-fold dilution (Figure 2A).  Cells of each line were 
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seeded into respective wells of 384-well white flat bottom plates (Corning) at a density of 
1,125 cells in 45µL of medium per well using a robotic dispenser (BioTek). 5µL of each 
drug at each concentration was added robotically by a Bravo Liquid Handler (Agilent) to 
the 384-well plates containing the ES cells such that compound from each well in the 
compound plate was added to 4 wells in the cell culture plate, therefore creating 4 
replicates of each concentration in each cell line (Figure 2B).  
To determine the effects of each compound on ES cells, viability was measured 
after 2 days and after 3 days utilizing a Cell-Titer Glo (CTG) ATP-based assay 
(Promega). The CTG assay determines the number of viable cells in culture by 
quantifying the amount of ATP present. When the CTG reagent is added to cells, it 
causes cell lysis and generation of a luminescence signal. This signal is proportional to 
the amount of ATP present which is directly proportional to the number of viable cells 
present in culture. 10µL of CTG was added to each well of respective plates, and after 15 
minutes incubation, luminescence was read using the FLUOstar Omega microplate reader 
(BMG Lab Tech).  Dose-response curves for each individual compound were generated. 
Appropriate IC50 and IC20 values were calculated from ATP measurements obtained 
after 2 days and 3 days of treatment using log-transformed, normalized data in Graph Pad 





Figure 2: Schema depicting the layout for dose response curves in ES cells. A) 
Example layout for compound plates to be tested for dose response curves. 96-well 
compound plates are created by serial dilution. Compound is then transferred 
robotically to a quadrant of cells in a 384-tissue culture plate B) containing ES cells 
resulting in 11 drug doses each in 5 different ES cell lines.   
 
Drug synergy analysis 
 
PARPi (AZD2281) plus ATRi (AZD6738) treatment of A673 and TC32 cell lines  
 
Compound combinations were tested in A673 cell line and TC32 cell line. 96-
well compound plates for each drug were created by serial dilution in respective media. 
The ATR inhibitor drug plate was made with a 10-point, two-fold dilution starting at 
100µM and with the PARP inhibitor drug plate containing a 6-point, two-fold dilution 
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starting at 100µM (Figure 3A). Cells were seeded in 384-well white flat bottom plates 
(Corning) at a density of 1,000 cells in 40µL of media per well using a robotic dispenser 
(BioTek). 5µL of each drug at each concentration was then added robotically by a Bravo 
Liquid Handler (Agilent) to the 384-well plates containing the ES cells such that 
compound from each well in the compound plate was added to 4 wells in the cell culture 
plate, therefore creating 4 replicates (Figure 3C). To determine the effects of agents on 
Ewing sarcoma cells, viability was measured after 2 days and after 3 days by adding 
10µL of Cell-Titer Glo ATP-based assay (Promega) to each well of the cell culture 
plates. After 15 minutes incubation, luminescence was read using the FLUOstar Omega 
microplate reader (BMG Lab Tech).  
 
PARPi (AZD2281), ATRi (AZD6738), plus SN38 treatment of A673 and TC32 cell lines 
 
Compound combinations were tested in the A673 and TC32 cell lines. 96-well 
compound plates for the ATR inhibitor and PARP inhibitor were created by serial 
dilution in respective media. The ATR inhibitor drug plate was made with a 10-point, 
two-fold dilution starting at 100µM and with the PARP inhibitor drug plate containing a 
6-point, two-fold dilution starting at 100µM. Three compound plates of SN38 were 
created with all compound wells at either 10nM, 5nM, or 2.5nM (Figure 3A-B). Cells 
were seeded into 384-well white flat bottom plates (Corning) at a density of 875 cells in 
35µL of media per well using a robotic dispenser (BioTek). 5µL of one SN38 drug 
concentration was added robotically by a Bravo Liquid Handler (Agilent) to all the 384-
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well plates containing the ES cells. Then 5µL of the ATR inhibitor and PARP inhibitor at 
each concentration was added robotically by a Bravo Liquid Handler (Agilent) to the 
384-well plates containing the ES cells such that compound from each well in the 
compound plate was added to 4 wells in the cell culture plate, therefore creating 4 
replicates (Figure 3C). To determine the effects of agents on Ewing sarcoma cells, 
viability was measured after 2 days and after 3 days by adding 10µL of Cell-Titer Glo 
ATP-based assay (Promega) to each well of the cell culture plates. After 15 minutes 
incubation, luminescence was read using the FLUOstar Omega microplate reader (BMG 
Lab Tech).  
 
Analysis   
 
To determine if drugs are synergistic the combination index (CI) was calculated 
from ATP measurements obtained after 2 days and 3 days of treatment using normalized 
data in Microsoft Excel. The Combination Index of Lowe Additivity for individual 
treatment combinations based on the Chou-Talalay Median Effect model was determined 






 , where (D)1 and (D)2 are the 
respective combination doses of Drug 1 and Drug 2 that yield 50% growth inhibition, and 
(Dx)1 and (Dx)2  are the respective doses of Drug 1 and Drug 2 alone that yield 50% growth 
inhibition. CI <0.7 are considered synergistic. CI = 0.7-1.3 are additive and CI > 1.3 are 






Figure 3: Synergy Analysis 384-well set up. A) Layout for compound plates to be 
tested for synergy. A) 96-well compound plates for ATRi and PARPi were created by 
serial dilution B) 96-well compound plates for SN38 were created at uniform 
concentration of either 10nM, 5nM, or 2.5nM C) Compounds were transferred 
robotically to a quadrant of wells in a 384-tissue culture plate containing cells resulting 
in a 11x7 combination dosing scheme without SN38 and with SN38 (green)  
 
Evaluating the ES cell viability effect of adding low doses of SN38 to PARPi and 




Compound combinations were tested in A673 cell line. 96-well compound plates 
for each drug were created by serial dilution in media. The ATR inhibitor drug plate was 
made with a 7-point, two-fold dilution starting at 32µM and with the PARP inhibitor drug 
plate containing a 7-point, two-fold dilution starting at 100µM. The SN38 drug was made 
with a 6-point, two-fold dilution starting at 20nM (Figure 4A). Cells were seeded into 
384-well white flat bottom plates (Corning) for each cell line at a density of 875 cells in 
35µL of media per well using a robotic dispenser (BioTek). 5µL of each drug at each 
concentration was then added robotically by a Bravo Liquid Handler (Agilent) to the 384-
well plates containing the ES cells such that compound from each well in the compound 
plate was added to 4 wells in the cell culture plate, therefore creating 4 replicates (Figure 
4B). To determine the effects of perturbations on Ewing sarcoma cells, viability was 
measured after 2 days and after 3 days by adding 10µL of Cell-Titer Glo ATP-based 
assay (Promega) to each well of respective plates. After 15 minutes incubation, 
luminescence was read using the FLUOstar Omega microplate reader (BMG Lab Tech). 
Dose-response curves for each combination were generated from ATP measurements 
obtained after 2 days and 3 days of treatment using log-transformed, normalized data in 
Graph Pad Prism 5.0 (GraphPad Software, Inc.).  
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Figure 4: Synergy Analysis with doses of SN38 384-well set up. A) Layout for 
ATRi, PARPi, SN38 compound plates to be tested for synergy. 96-well compound 
plates for ATRi, PARPi, and SN38 were created by serial dilution. Compound was 
transferred robotically to a quadrant of wells in a 384-tissue culture plate B) containing 





Anti-Ewing Sarcoma effect of PARP inhibition combined with ATR inhibitor  
  
In order to determine whether inhibition of PARP was synergistic with inhibition 
of ATR in Ewing Sarcoma, I first confirmed that Ewing sarcoma cells are sensitive to 
both PARP inhibitors and ATR inhibitors alone. I found that the PARP inhibitor, 
AZD2281, and ATR inhibitor, AZD6738), impaired cell viability at micromolar 
concentrations. 50% reduction of cell viability occurred after 2 and 3 days respectively of 
treatment with 1.382µM of PARP inhibitor alone and 0.506µM of ATR inhibitor alone in 
A673 cells and 2.234µM of PARP inhibitor alone and 0.379µM of ATR inhibitor alone 






Figure 5: IC50 Determination of PARP Inhibitor (AZD2281) and ATR Inhibitor 
(AZD6738) in ES cell lines. Nonlinear regression fit of Relative Viability to DMSO v. 
log [drug] on Day 3 for A) PARP inhibitor, B) ATR inhibitor treatments in A673 (blue 
circle), TC32 (black square), TC71 (black triangle), SKPNDW (green inverted 
triangle), and EW8 (red diamond) ES cell lines. Relative viability was calculated by 
normalizing to cells treated with DMSO only. Shown are the mean of four replicates 
+/- SD. 
 
 Next, I tested whether PARP inhibitors were synergistic with ATR inhibitors in 
A673 and TC32 Ewing Sarcoma cell lines. In the A673 cell line treated with a range of 
PARP inhibitor and ATR inhibitor concentrations, I found that after 2 days of treatment 
multiple concentrations of drug combinations were synergistic with a Combination Index 
<0.7 indicating synergy (Figure 6A).  The synergistic activity of the combination was 
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also evident in A673 cells treated for 3 days with the same combinations (data not 
shown).  In TC32 cell line treated with combinations of PARP and ATR inhibitors, I also 
found that after two and three (data not shown) days of treatment, multiple dose 
combinations demonstrated anti-Ewing activity (Figure 6B).  
 
Figure 6: The combination of PARP and ATR inhibition has synergistic anti-
Ewing activity. Scatter plot of the log10 normalized Combination Index value vs. 
fractional inhibition of viability for each treatment combination of PARP inhibitor and 
ATR inhibitor after 2 days in A) A673 B) TC32 Ewing sarcoma cell lines. Treatment 
combinations plotted are in Figure 3A. Combinations with a CI <0.7 (indicating 
synergy) were plotted in red, CI = 0.7-1.3 (indicating additivity) are plotted in white, 
and CI >1.3 (indicating antagonism) are plotted in black.   
 




Although PARP inhibitors and ATR inhibitors exhibit synergistic activity alone, it 
is possible that synergy between these two agents could be enhanced after treatment with 
low-doses of DNA damaging agents since genomic sequencing data has established a low 
rate of somatic mutation in ES suggesting limited active DNA damage in ES compared to 
other cancers. If low doses of DNA damaging agent can enhance synergy between PARP 
inhibitors and ATR inhibitors, then it is possible that lower doses of these two agents can 
cause efficacy with decreased toxicity. In order to determine if low-doses of a DNA 
damaging agent enhances synergy between PARP and ATR inhibitors, I added low-doses 
of SN38, an active metabolite of irinotecan which is a DNA damaging agent currently 
utilized in the relapse setting, to the PARP inhibitor and ATR inhibitor combination.  
In order to determine whether damaging DNA by treating cells with SN38 will 
induce greater synergy in combinations of PARP inhibitors and ATR inhibitors, I first 
identified a dose of SN38 that had minimal viability effect on ES cells by performing a 
dose response curve in two ES cells, A673 and TC32. I found that the concentration of 
SN38 that inhibited cell growth by 20% (IC20) after day 2 of treatment was 1.95nM in 
the A673 cell line and 0.97nM in the TC32 cell line (Figure 7A-B). The IC20 after 3 







Figure 7: Dose-response curves of ES cell lines treated with the active metabolite 
of irinotecan, SN38. Nonlinear regression fit of Relative Viability to DMSO v. log of 
[SN38] plotted for A) Day 2 and B) Day 3 treatments in A673 (blue circle), TC32 
(black square), TC71 (black triangle), SKPNDW (green inverted triangle), and EW8 
(red diamond) ES cell lines. Relative viability was calculated by normalizing to cells 
treated with DMSO only. Shown are the mean of four replicates +/- SD. 
 
Next, I examined whether treatment with PARP and ATR inhibitors remained 
synergistic in cells exposed to low doses of SN38 in two Ewing sarcoma cell lines. In 
A673 cells, I found that treatment with 0.5nM or 1nM of SN38 alone had a minimal 
effect on cell viability and that the combination of PARP and ATR inhibition remained 
synergistic in the presence of SN38 at these concentrations. Similarly, in TC32 cells, 
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treatment with 0.25nM or 0.5nM of SN38 alone also had minimal effect on cell viability 
while the combination of PARP and ATR inhibitors had synergistic anti-Ewing activity 
in the presence of SN38 at these doses (Figure 8 and 9).  
Figure 8: PARP inhibitor and ATR inhibitor combinations with low dose SN38 
are synergistic in A673 ES cell line. Scatter plot of the log10 normalized 
Combination Index value vs. fractional inhibition of viability of A673 cells for each 
treatment combination of PARP inhibitor and ATR inhibitor plus A) 0.5nM of SN38 
B) 1nM of SN38 after 2 Days. Treatment combinations plotted are in Figure 3B. 
Combinations with a CI <0.7 (indicating synergy) were plotted in red, CI = 0.7-1.3 
(indicating additivity) are plotted in white, and CI >1.3 (indicating antagonism) are 




Figure 9: PARP inhibitor and ATR inhibitor combinations with low dose SN38 
are synergistic in TC32 ES cell line. Scatter plot of the log10 normalized 
Combination Index value vs. fractional inhibition of viability of TC32 cells for each 
treatment combination of PARP inhibitor and ATR inhibitor plus A) 0.25nM of SN38 
B) 0.5nM of SN38 after 2 Days. Treatment combinations plotted are in Figure 3B. 
Combinations with a CI <0.7 (indicating synergy) were plotted in red, CI = 0.7-1.3 
(indicating additivity) are plotted in white, and CI >1.3 (indicating antagonism) are 
plotted in black. 
 
Next, I tested whether the treatment of ES cells with SN38 sensitized them to 
combination treatment of PARP and ATR inhibition. To do this, I selected doses of 
PAPR and ATR inhibitors that were synergistic in the A673 cell lines in the absence of 
SN38.  Cells were plated in 384-well format and treated with a range of selected 
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concentrations of PARP inhibitor and ATR inhibitor either alone or in combination with 
a range of SN38 doses predicted to have minimal effect on cell viability alone. Cells were 
treated with this combination for 2 days and 3 days to determine whether doses of SN83 
resulted in an increased sensitivity to lower concentrations of PARP inhibitor and ATR 
inhibitor. I found that 0.5nM and 1nM of SN38 had minimal effect on A673 viability 
alone (Figure 10), and that these doses substantially lowered the doses of PARP inhibitor 
and ATR inhibitor required to inhibit viability of cells (Figure 11).  These studies 
demonstrate that low-dose treatment of ES cells with non-toxic concentrations of SN38 
sensitizes them to treatment with combinations of inhibitors of DNA-damage repair.  
 
Figure 10: Low dose SN38 has minimal effect on cell viability. Box Plot of Relative 
Viability to Day 0 for cells treated with six concentrations of SN38 and DMSO at Day 





Figure 11: Low dose SN38 sensitizes A673 cells to ATR and PARP inhibition. 
Nonlinear regression fit of cell viability relative to SN38 alone on Day 3 when treated 
with combinations of PARP inhibitor, ATR inhibitor and SN38.  Shown are the mean 






Implications of Findings 
 
Overall survival for patients with ES has remained relatively constant for the past 
20 years. Therefore, there is a need for finding new candidate drug targets for treatment of 
this disease. Recently, studies demonstrate that ES cells have a deficiency in DNA-damage 
repair that mimics BRCA-deficient tumor cells (Gorthi et al., 2018).  Furthermore, like 
other BRCA tumors, ES cells are sensitive to PARP inhibition in vitro and in vivo. 
However, phase II studies of a PARP inhibitor, Olaparib,  as a single agent for the treatment 
of patients with refractory ES showed no significant disease response (Choy et al., 2014). 
Single-agent therapy is rarely effective in the treatment of cancer. Therefore, in this study 
we aimed to identify a rational approach to combine therapy with PARP inhibition in ES. 
ATR signaling responds to ssDNA breaks and regulates several DNA repair 
pathways.  Preclinical studies have shown that BRCA deficient ovarian and breast 
cancers and ATM deficient gastric cancers are sensitive to ATR inhibitors (Peasland et 
al., 2011)  (Min et al., 2017). Therefore, several ATR inhibitors are being studied in early 
phase clinical trials which explore the safety of combining ATR inhibitors with other 
anti-cancer therapies (clinicaltrials.gov, NCT02640199, NCT02487095).  
Previous studies suggest a potential role for ATR inhibitors in the treatment of 
ES. One study found that ATR inhibition can selectively kill cancer cells lines with a 
deficiency in ATM (Reaper et al., 2011), and quantitative PCR utilizing TaqMan probes 
for 46 DNA repair genes found downregulation of ATM in ES cell lines relative to levels 
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in OS cell lines (Stewart et al., 2014). This suggests that ES cells would be more sensitive 
to ATR inhibitors than cells with normal levels of ATM. In addition, ATR signaling is 
involved in responding to replication stress (RS), and ES exhibits increased levels of RS 
in part due to an accumulation of R loops (Gorthi et al., 2018). 
Previous preclinical studies have explored ATR inhibitors in ES. In vitro 
experiments found that two independent ATR inhibitors (ETP-46464 and AZ20) as single 
agents had increased toxicity to ES cell lines than human primary cell lines or non-ES 
osteosarcoma cells line. The expression of EWS-FLI or EWS-ERG translocations in non-
ES cell lines also cause increased sensitivity to ATR inhibitors.  Additionally, in ES 
xenografts (A4573) ATR inhibitors (AZ20 or MSC253) alone cause a significantly 
decreased tumor size and increased accumulation of cells with pan-nuclear γH2AX (a 
marker of DNA damage) compared to vehicle (Nieto-Soler et al., 2016). This data 
combined with that from previously published work, provide support for further testing 
of ATR inhibitors in patients with ES.   
Through our in vitro investigations, we found that the PARP inhibitor, AZD2281, 
combined with the ATR inhibitor, AZD6738, demonstrated points of synergistic anti-
Ewing Sarcoma activity. There is also evidence that PARP inhibitors combined with 
ATR inhibitors in cancers that commonly contain BRCA deficiencies have synergistic 
anti-cancer effects (Kim et al., 2017). Currently, there is a Phase I study combining an 
ATR inhibitor with carboplatin, or Olaparib, or PD-L1 antibody in patients with 
advanced solid malignancies, and a Phase II study combining an ATR inhibitor, 
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AZD6738, and a PARP inhibitor, Olaparib, in recurrent ovarian cancer (clinicaltrials.gov, 
NCT03462342, NCT02264678). These adult studies will provide dosing information for 
a possible future Phase II study combining these agents in young adults and teen patients 
with ES.  
Through our in vitro investigations, we also discovered that PARP inhibition combined 
with ATR inhibition have synergistic anti-Ewing activity when combined with low-dose 
non-toxic levels of SN38, and that low-dose treatment of ES cells with non-toxic 
concentrations of SN38 sensitizes them to treatment with combinations of inhibitors of 
DNA-damage repair. By normalizing cell viability to SN38 alone, we were able to 
determine that SN38 sensitizes ES cells to the combination of PARP and ATR inhibitors. 
These three agents have not yet been combined in the clinic, however additional preclinical 
in vitro evidence shows that combinations of PARP inhibitor and ATR inhibitors at non-
toxic concentrations produced a dramatic decrease in IC50 of SN38 across all colon cancer 
cell lines (Abu-Sanad et al., 2015). Additionally, the combination of an ATR inhibitor, a 
PARP inhibitor and a DNA damaging agent (Methyl Methanesulfonate) have been 
explored in human fibroblasts. It was found that expression of ATRkd (dominant negative 
kinase-dead form of ATR), but not wild-type ATR, sensitized fibroblasts to the 
combination of Methyl Methanesulfonate (MMS) and 4-AN (PARP inhibitor). In addition, 
this study suggests the involvement of the ATR-mediated damage response pathway in 
cells treated with MMS and 4-AN (Horton et al., 2007).  
In the clinic, both PARP inhibitors and ATR inhibitors alone are currently being 
investigated in combination with DNA damaging agents in patients with solid tumors. An 
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ongoing Phase I study is assessing the safety of combing an ATR inhibitor, AZD6738, with 
radiation therapy (clinicaltrials.gov, NCT02223923). An additional early phase trial 
exploring a PARP inhibitor in combination with irinotecan in children and young adults 
with recurrent/refractory solid tumors shows that not all patients respond to treatment 
(Federico et al., 2017). Given that few patients respond to single-agent therapy plus a DNA 
damaging agent, it is reasonable to continue exploring the combination of two targeted 
therapies (e.g. PARP inhibitor and ATR inhibitor) with a DNA damaging agent like 
irinotecan. 
 
Future Studies  
Additional in vitro studies  
 In order to justify a treatment combining three agents instead of two agents, we 
propose exploring the effect on cell viability of low-doses of SN38 combined with PARP 
inhibitors alone and low-doses of SN38 combined with ATR inhibitors alone to 
determine if ES cells are more sensitive to the combination of the three agents than to 
low-doses of SN38 plus either agent alone. We also propose performing synergy analysis 
on additional ES cell lines to ensure that the trend holds up in ES cell lines with different 
genotypes.  
In addition, we propose exploring the mechanisms of synthetic lethality of PARP 
inhibitors and ATR inhibitors with and without low doses of SN38 in ES. One study 
suggests that in BRCA deficient cancers, unrepaired DNA breaks accumulate in the 
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absence of PARP which can cause replication associated DSBs that are detected by 
γH2AX. This activates ATR to promote repair by homologous recombination as detected 
by Rad51 foci. Cells treated with ATR inhibitors, allow replication lesions to remain 
unrepaired leading to cell death (Peasland et al., 2011). We propose treating ES cells with 
DMSO, each drug alone, and each drug combination and performing immunofluorescent 
detection of DNA DSB and repair by homologous recombination by through γH2AX and 
Rad51 formation respectively. We also propose that after treating ES cells with DMSO, 
each drug alone, and each drug combination, we will perform a Western blot analysis for 
PARP levels (given that AZD2281 is a PARP inhibitor), p-Chk1 levels normalized to 
total-Chk1 levels (given that AZD6738 is an ATR inhibitor and activated ATR 
phosphorylates Chk1), pRAD51 levels normalized to total-Rad51 levels (to measure 
changes in homologous recombination), and pDNA-PK levels normalized to total-DNA-
PK levels (to measure any changes in non-homologous end joining DNA repair 
pathway).  
We also propose performing an analysis of the cell cycle and apoptosis after 
treatment of each drug combination to provide insight into how each drug alone or in 
combination impairs cell growth and leads to apoptosis. This analysis can be performed 
utilizing propidium iodide (DNA binding dye) and flow cytometry methods. Previous 
studies found that treatment of ATR inhibitor combined with DNA damaging agent alone 
or with DNA damaging agent plus PARP found an increase in G2-M arrest in ovarian 
cancer cell lines and colon cancer cell lines respectively (Peasland et al., 2011) (Abu-




Preclinical in vivo study 
Given the low number of pediatric ES patients, it is likely that there will be 
limited opportunities for Phase II studies combining ATR inhibitor and PARP inhibitor in 
ES. Therefore, it is important to determine if adding low-dose irinotecan to create active 
DNA damage enhances synergistic activity between ATR inhibitors and PARP inhibitors 
in vivo. In addition, an in vivo study will provide insight on the negative side effects 
associated with the PARP inhibitor plus ATR inhibitor combination with and without low 
doses of SN38.  
We first propose setting up an in vivo tolerability study to estimate the preclinical 
maximal tolerated dose (MTD) of the drug combination of AZD6738, AZD2281 and 
irinotecan. Single-agent MTDs are established for each of these agents (Checkley et al., 
2015) (Weston et al., 2010) (Stewart et al., 2014). We will first determine the doses at 
which AZD2281 plus AZD6738 can be tolerated, and then will test the tolerated dose of 
the combination of AZD2281 and AZD6738 plus low-dose irinotecan in mice. Animals 
will be weighed daily to ensure that drugs have no toxic effect.     
After we have performed a tolerability study, we propose doing a 
pharmacokinetic study evaluating the timing of clearance of each drug alone and in the 
following combinations: AZD2281 plus AZD6738 alone and AZD2281 and AZD6738 
plus low-dose irinotecan.  If the clearance of each drug alone is significantly different 
from clearance of the combinations, then we will explore further ways to limit differences 
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in clearance.  We also propose completing a pharmacodynamics (PD) study to 
demonstrate on-target activity of AZD2281 and AZD6738.  After dosing for five days, 
the animals will be sacked and tumors extracted for Western blot analysis. Since 
AZD2281 is a PARP inhibitor, we will measure protein levels of PARP. Since AZD6738 
is an ATR inhibitor and ATR signaling causes phosphorylation of pCHK1, we will 
measure protein levels of ATR, pCHK1 and CHK1. In addition, given that AZD2281 is a 
PARP inhibitor, we will measure protein levels of PARP.  
Finally, we propose performing a preclinical phase II study comparing the 
efficacy of each drug alone and in combinations in ES mouse xenograft models. The aim 
will be to demonstrate efficacy of AZD2281 and AZD6738 with and without low doses 
of irinotecan on tumor progression and survival. Tumor size over time and over-all 




This study identifies ATR inhibitors plus PARP inhibitors alone or in combination 
with reduced levels of irinotecan as a potential therapy for patients with ES. Since there 
are several PARP inhibitors and ATR inhibitors in various stages of clinical 
development, we believe these classes of compounds warrant further investigation for 
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